Question 1

What is Terese Hammond?

Accepted Answer

Terese Hammond is a Person.

Question 2

How often does Terese Hammond appear in global news?

Accepted Answer

Tracked across 3 news events drawn from 21 articles.

Question 3

When was Terese Hammond first tracked by Ergen?

Accepted Answer

First tracked on Apr 01, 2026.

Question 4

When was Terese Hammond last mentioned in news?

Accepted Answer

Last active on Aug 06, 2026.

Question 5

What is Terese Hammond's current news sentiment?

Accepted Answer

Aggregate sentiment score: 20 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is Terese Hammond in global news coverage?

Accepted Answer

Attention score of 4, derived from article volume and coverage intensity across 3 events.

Question 7

What is the most recent event involving Terese Hammond?

Accepted Answer

MiNK Therapeutics Doses First Patient (May 28, 2026, 6 articles).

Question 8

How did the "MiNK Therapeutics Doses First Patient" event impact Terese Hammond?

Accepted Answer

As Head of R&D at MiNK Therapeutics, Terese Hammond provided insights into the trial's design and its potential to address immune dysfunction in critically ill patients.

Question 9

How did the "MiNK Therapeutics agenT-797 Data" event impact Terese Hammond?

Accepted Answer

Terese Hammond, M.D., Head of Inflammatory and Pulmonary Diseases at MiNK Therapeutics, presented the poster and provided commentary on the findings.

Question 10

How did the "MiNK agenT-797 Phase 2 pneumonia data" event impact Terese Hammond?

Accepted Answer

Dr. Terese Hammond presented the data and leads the inflammatory and pulmonary diseases program at MiNK, contributing to the trial's credibility.

Question 11

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.